TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06510868

Intervention type: RADIATION
Intervention: Peptide receptor radionuclide therapy (PRRT)
Description: Specialized type of radionuclide therapy used to treat neuroendocrine tumors.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Patients will have approximately 5 ml of blood drawn 6,12,24,36,48, 60 months and at the time of MDS/AML diagnosis on follow up. Genomic DNA will be extracted from serum sample using the Qiagen QIAamp DNA Mini Kit. Single-molecule molecular inversion probes (smMIPs) will be used to detect mutations. Single nucleotide variants (SNVs), short insertions and deletions (indels), and mutated myeloid genes will be captured (e.g PPM1D, DNMT3A, TET2, TP53).
Study: NCT06065930

Intervention type: DEVICE
Intervention: Subcutaneous microdialysis
Description: Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.

Intervention type: DEVICE
Intervention: Subcutaneous microdialysis
Description: Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.

Intervention type: DEVICE
Intervention: Subcutaneous microdialysis
Description: Group with Ob-IS participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Ob-IR participants, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.~Group with Leans, collection of abdominal subcutaneous interstitial dialysates after an overnight´s fast for later measurements of metabolites and peptides eg galectin-1.
Study: NCT04997798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Pyrotinib Exemestane Dalpiciclib
Description: Early triple positive breast cancer patients receive combination regimen of Dalpiciclib in Combination With Exemestane and Trastuzumab plus pyrotinib
Study: NCT06360276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Exercises
Description: A quasi-experimental research was conducted in the main University Hospital, Alexandria, Egypt. women practiced seated exercises

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Rehabilitation
Description: Women received Psycho-educational Rehabilitation, including mindfulness breathing, problem-solving training, cognitive re-framing technique, and thought stopping.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Women received routine health education in the unit, where nurses provided general instructions about the postoperative activities for women with breast cancer.
Study: NCT06499116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 25-100 mg/12h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 2,5-10 mg mg/24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 10-75 mg/24h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Treatment will be prescribed for GPs and they will decide the specific dosage 20-120 mg/12h.
Study: NCT06507514

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: blinatumomab and auto-HSCT sandwich  strategy
Description: The patients received sequential infusion of blinatumomab after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after infusion. Following successful stem cell collection, autologous stem cell transplantation was conducted. Starting from the third month after autologous stem cell transplantation, the second maintenance treatment with brentuximab vedotin was administered, with one cycle every three months, for a total of four cycles. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
Study: NCT06120101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflexology Massage
Description: The researcher washed his hands with an antibacterial soap before cleaning the patient's feet. The feet were cleaned according to the patient's preference; To wash feet with water or use disposable wet cloth. The patients were placed in a supine position on the bed in the room and their joint points were supported. The researcher stood at the end of the patient's bed during treatment. Unscented sesame oil at room temperature was used to provide lubrication during reflexology. The application started with the patient's right foot. The foot was first relaxed by applying effleurage, shaking, rotation and stretching methods. During the application, the researcher used the fingers of the other hand while supporting the patient's foot with one hand, and the thumb and caterpillar technique was mostly used. In other applications, the index finger and other fingers were used. The training ended by applying solar plexus pressure to both feet.
Study: NCT05544786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir/ ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir tablets under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/Ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in water under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/Ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in infant formula under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir/ritonavir
Description: Single oral dose of nirmatrelvir/ritonavir mixed in vanilla pudding under fed condition
Study: NCT04759365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN51
Description: ASN51 formulation for oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo formulation for oral capsule
Study: NCT06195449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ALKASITE RESTORATIVE MATERIAL
Description: Restorative material for primary teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer Cement
Description: Restorative material for primary teeth
Study: NCT06234436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma exchenge
Description: Plasma exchange will be conducted. The substitution fluid will be plasma from ha healthy donor.
Study: NCT05479149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training protocol with the cervical device for treatment (CDAT).
Description: Endurance training program of deep cervical flexors and deep cervical extensors with the cervical device for treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training protocol
Description: Endurance training program of deep cervical flexors and deep cervical extensors with the conventional protocol.
Study: NCT04514562

Intervention type: DEVICE
Group type: OTHER
Intervention: NeVa Stent Retrievers
Description: mechanical neurothrombectomy
Study: NCT04090476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During each of the exercise sessions the LSVT Big daily exercises will be performed along with functional tasks and gait/balance tasks. The functional tasks and gait/balance tasks will change weekly to monthly and all activities will be modified to the participant's mobility level.
Study: NCT05044416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VieScope
Description: intubation with VieScope laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscopy
Description: intubation with videolaryngoscope
Study: NCT06509321

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal loupe-assisted varicocelectomy (LV)
Description: to assess the efficacy and safety of sub inguinal loupe-assisted varicocelectomy with nitroglycerin instillation as a vasodilator and compare its results versus subinguinal microscopic varicocelectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subinguinal microscopic varicocelectomy (MV)
Description: we are using surgical microscope to perform varicocelectomy as control group
Study: NCT06390449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot intervention
Description: Kahoot, one of the WEB-2.0 tools, will be applied to students who are second-year students of the nursing department and taking the basic principles and practices in nursing course after the course.
Study: NCT06207006

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eConquerFear-HK
Description: The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Cancer Care
Description: Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
Study: NCT06369532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
Study: NCT05532553

Intervention type: DEVICE
Intervention: Carotid Doppler U/S
Description: Measurement of carotid intima media thickness by carotid doppler ultrasound

Intervention type: DEVICE
Intervention: Carotid Doppler U/S
Description: Measurement of carotid intima media thickness by carotid doppler ultrasound
Study: NCT06482073

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT06510959

Intervention type: OTHER
Group type: OTHER
Intervention: Digital course
Description: The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
Study: NCT05227898

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Attune™
Description: People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Cerena™
Description: People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
Study: NCT05880810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Dexcom G6 PRO
Description: Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
Study: NCT06547892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: To dilute vasopressin, an ampoule containing 20 IU/ml (1 ml) of vasopressin will be used, which will be mixed with 100 ml of 0.9% physiological solution, resulting in a solution with a concentration of 0.2 IU/ ml. In this study, both central and peripheral vein infusion will be permitted.~The vasopressin administration protocol will consist of an initial dose of 0.02 IU/min (equivalent to 6 ml/h), which can be increased to 0.03 IU/min (9 ml/h) if the mean arterial pressure (MAP) is less than or equal to 65 mmHg. On the other hand, if MAP exceeds 90 mmHg, the dose can be reduced to 0.01 IU/min (3 ml/h). The minimum period for adjusting the drug dosage should be one hour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% saline solution
Description: Similar to the intervention protocol, but using a placebo composed of 0.9% saline solution.
Study: NCT04345718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Buprenorphine
Description: XR-BUP administration prior to hospital discharge will increase engagement in OUD care on the 34th day following hospital discharge more than is currently afforded by ACS TAU approaches (e.g., methadone, SL-BUP, and naltrexone).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Community standard medication for opioid use disorder (e.g., methadone, sublingual buprenorphine, naltrexone) initiated prior to hospital discharge.
Study: NCT05491421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT002
Description: Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings
Study: NCT06187025

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
Description: Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)

Intervention type: OTHER
Group type: OTHER
Intervention: Ecological Momentary Assessment (EMA)
Description: Daily EMA evaluations during 12 weeks
Study: NCT05458856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin embonate 22.5 mg
Description: A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
Study: NCT06409819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phage therapy
Description: phage therapy will consist of an individualized combination of lytic phages that are active against the participant's E. coli/K. pneumoniae isolates and will be administered intravenously twice daily for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: Participants assigned to the control arm will start a 7-day course of intravenous sterile normal saline (placebo) administered twice daily.
Study: NCT06469502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching Exercises
Description: Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening Exercises
Description: Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
Study: NCT05501535

Intervention type: DEVICE
Intervention: ND:YAG LASER
Description: The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
Study: NCT05562349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic Acid Only Product
Description: Drug will be given in 250mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active medication - identical to drug capsule
Study: NCT05552768

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone level-driven placement
Description: The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological width-driven placement guidelines
Description: Biological width-driven placement guidelines
Study: NCT04745598

Intervention type: BEHAVIORAL
Intervention: Control group: Dental Model
Description: - Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.

Intervention type: BEHAVIORAL
Intervention: Computer-assisted teaching format group
Description: - Patients receive a Powerpoint presentation containing:
Study: NCT05999110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
Study: NCT05491746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye4
Description: Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the patient's best corrected vision with or without glasses/contact lenses
Study: NCT05566262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bodewell Calming Cream
Description: Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
Study: NCT04317326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications group (Control)
Description: It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic NIV
Description: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP treatment group
Description: In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIV treatment groups
Description: In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
Study: NCT05826977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CASI-Plus
Description: See arm description